Six months after its unveiling, the IRO platform is now being deployed to customers Six months after its unveiling, the IRO platform is now being deployed to customers
Original post:
Ori Biotech Announces First Customer Deliveries of IRO to Leading CDMOs and Commercial CGT Manufacturers
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission
Read more here:
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
BOSTON, MASSACHUSETTS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced a well-attended Techwatch Light meeting hosted by the Biomedical Advanced Research and Development Authority (BARDA) to introduce the company to the government, and help facilitate and direct the Company’s approach toward finding programs within the government capable of funding its development initiatives.
Read more:
Bioxytran Announces Government Interest After Initial BARDA Techwatch Light Meeting
Company to Host International Roadshow the Week of January 13, 2025
Link:
Renovaro Issues Shareholder Letter and Provides Corporate Update
NOVATO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial. The trial will be conducted at CMAX, one of Australia’s leading clinical research centers, in partnership with Monash University. This effort will be led by Dr. Stephen Nicholls of the Victorian Heart Institute (VHI), a distinguished leader in cardiovascular medicine. In addition to a traditional SAD/MAD phase 1 trial, the authorization includes an allowance to enroll 12 patients with Acute Coronary Syndrome (ACS) to assess the safety of UDP-003 in individuals with plaque buildup, as well as to explore anecdotal evidence of efficacy. This represents a critical first step in evaluating the potential impact of our therapy in a population with high unmet need.
Read the original post:
Cyclarity Therapeutics Secures Approval for First-in-Human Clinical Trial
Achieved record fourth quarter and full-year 2024 sepsis product revenues Achieved record fourth quarter and full-year 2024 sepsis product revenues
Read more here:
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
Continue reading here:
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue
See the article here:
Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million
REDWOOD CITY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announce compelling results from in vivo studies of icovamenib in combination with semaglutide.
See the original post here:
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET.
Original post:
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference